重大新闻！海底捞强势收涨逾4%，机构看好公司后续业绩稳健增长

海底捞强势收涨逾4%，机构看好公司后续业绩稳健增长

北京 - 6月13日，海底捞（06862）在港股市场强势收涨3.96%，报收16.80港元，成交额达1.78亿港元。业内机构普遍看好海底捞后续业绩的稳健增长。

招商证券指出，作为火锅行业的龙头企业，海底捞在服务、管理、品牌和供应链方面依然拥有业界领先的优势。尽管近期受到疫情影响，但海底捞的翻台率已经回暖，展现出强劲的抗压能力和韧性。

此外，海底捞稳健的开店计划、独特的加盟模式以及新品牌“嗨捞”的孵化进程也值得关注。招商证券预计，随着各项业务的逐步恢复，海底捞将有望实现业绩的稳健增长，并持续为股东带来丰厚的回报。

其他机构也对海底捞后市表现持乐观态度。

中信证券表示，海底捞的品牌影响力和市场号召力依然强劲，随着疫情防控措施的优化，餐饮行业有望迎来复苏，海底捞的业绩将得到进一步提振。

开源证券则认为，海底捞积极探索新的业态和模式，例如社区营运中心和小酒馆等，这将有利于公司拓展新的客群和增长点，增强其核心竞争力。

总体而言，机构普遍看好海底捞的未来发展前景。 随着疫情影响的逐步消退和各项业务的逐步恢复，海底捞有望迎来业绩的稳健增长，并继续引领火锅行业的潮流。

以下是一些可以补充到新闻稿中的其他信息：

• 海底捞近期推出的新品和优惠活动
• 海底捞在海外市场的扩张计划
• 海底捞对食品安全和环保的取り組み
• 海底捞的企业文化和社会责任

请注意，以上信息仅供参考，不构成任何投资建议。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.